metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-10 and is reviewed periodically as new material appears.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Awards == Li was an expert in diversified areas, including endocrinology, biochemistry, and peptide synthesis. He not only was a widely recognized leader in pituitary-secreted research for his contribution in hormone and growth factors, but also greatly advanced the field of protein chemistry. All of his research had direct impact on clinical applications, especially in growth and fertility. It is estimated that he had published more than 1,000 research papers and had collaborated with more than 300 people. In addition, he was also the recipient of a lot of honors (more than 25). The most significant ones are as follows:
=== Anna Gearing === Anna Gearing (Elena Saurel) is the head of FutureDawn Partners, a socially conscious investment fund. Despite her ethical business philosophy, Anna is shown to have expensive personal tastes, and micromanages employees at her fund. She has two daughters, with her longtime portfolio manager Petra Koenig as their godmother. Anna first appears as a client of Pierpoint, with Yasmin Kara-Hanani hedging her FX exposure. Harper meets Anna at a Pierpoint-organized duck shoot in Wales tied to healthcare startup Rican, where Anna bluntly assesses Rican as fundamentally underperforming and incapable of delivering on its social mission. Harper uses this insight to convince Jesse Bloom to buy out Anna’s stake—after already selling him $3.3 billion in shares—securing his controlling interest and long-term profit. After Harper is fired from Pierpoint, she joins FutureDawn as Anna’s executive assistant, but quickly aligns herself with Petra, who grows disillusioned with Anna’s leadership. Tensions peak when Harper helps Petra hedge Lumi IPO exposure by buying credit default swaps on fossil-fuel assets, directly contradicting FutureDawn’s ethical stance. Harper and Petra ultimately break away to form their own hedge fund, publicly announcing the move at a Swiss climate conference attended by Anna.
He then ended the press conference promptly at 19:00 as journalists hurried from the room. After the press conference, Schabowski sat for an interview with NBC News anchor Tom Brokaw in which he repeated that East Germans would be able to emigrate through the border and the regulations would go into effect immediately.
Sources: en.wikipedia.org
Natriuretic peptide precursor C, also known as NPPC, is a protein that in humans is encoded by the NPPC gene. The precursor NPPC protein is cleaved to the 22 amino acid peptide C-type natriuretic peptide (CNP).
Focke-Wulf Flugzeugbau AG (German pronunciation: [ˌfɔkəˈvʊlf]) was a German manufacturer of civil and military aircraft before and during World War II. Many of the company's successful fighter aircraft designs were slight modifications of the Focke-Wulf Fw 190. It is one of the predecessor companies of today's Airbus.
=== Infrared light detection === Graphene reacts to the infrared spectrum at room temperature, albeit with sensitivity 100 to 1000 times too low for practical applications. However, two graphene layers separated by an insulator allowed an electric field produced by holes left by photo-freed electrons in one layer to affect a current running through the other layer. The process produces little heat, making it suitable for use in night-vision optics. The sandwich is thin enough to be integrated in handheld devices, eyeglass-mounted computers and even contact lenses.
Sources: en.wikipedia.org
=== Molecular biology === In 1954, at the age of 37, Crick completed his PhD thesis: "X-Ray Diffraction: Polypeptides and Proteins" and received his degree. Crick then worked in the laboratory of David Harker at Brooklyn Polytechnic Institute, where he continued to develop his skills in the analysis of X-ray diffraction data for proteins, working primarily on ribonuclease and the mechanisms of protein synthesis. David Harker, the American X-ray crystallographer, was described as "the John Wayne of crystallography" by Vittorio Luzzati, a crystallographer at the Centre for Molecular Genetics in Gif-sur-Yvette near Paris, who had worked with Rosalind Franklin. After the discovery of the double helix model of DNA, Crick's interests quickly turned to the biological implications of the structure. In 1953, Watson and Crick published another article in Nature which stated: "it therefore seems likely that the precise sequence of the bases is the code that carries the genetical information".
=== Brand names === Estradiol cypionate has been marketed under the brand names Cicloestradiolo, D-Est, depGynogen, Depo-Estradiol, Depoestra, Depofemin, Depogen, Dura-Estrin, E-Cypionate, E-Ionate, Estradep, Estro-Cyp, Estrofem, Estroject, Estromed-PA, Estronol, Femovirin, Neoginon Depositum, Oestradiol-Retard, Pertradiol, Spendepiol, and T-E Cypionate, among others.
== Production == 60Co does not occur naturally on Earth in significant amounts, so 60Co is synthesized by bombarding a 59Co target with a thermal neutron source - in a commercial or industrial context, that means a nuclear reactor. The CANDU reactors can be used to activate 59Co, by substituting the control rods with cobalt rods. In the United States, as of 2010, it is being produced in a boiling water reactor at Hope Creek Nuclear Generating Station. The cobalt targets are substituted here for a small number of fuel assemblies. Still, over 40% of all single-use medical devices are sterilized using 60Co from Bruce nuclear generating station. The reaction in all cases is
Many homes have a large kitchen area devoted to preparation of meals and food, and may have a dining room, dining hall, or another designated area for eating. Most societies also have restaurants, food courts, and food vendors so that people may eat when away from home, when lacking time to prepare food, or as a social occasion. At their highest level of sophistication, these places become "theatrical spectacles of global cosmopolitanism and myth." At picnics, potlucks, and food festivals, eating is the primary purpose of a social gathering. At many social events, food and beverages are made available to attendees. People usually have two or three meals a day. Snacks of smaller amounts may be consumed between meals. Doctors in the UK recommend three meals a day (with between 400 and 600 kcal per meal), with four to six hours between. Having three well-balanced meals (described as: half of the plate with vegetables, 1/4 protein food as meat, [...] and 1/4 carbohydrates as pasta, rice) will then amount to some 1800–2000 kcal, which is the average requirement for a regular person. In jurisdictions under Sharia law, eating may be proscribed for Muslim adults during the daylight hours of Ramadan.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.